GT BIOPHARMA, INC. Operating Lease, Liability, Current
GT BIOPHARMA, INC. (GTBP) had Operating Lease, Liability, Current of $30.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-15.
Financial Statements › Notes
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2025-02-21
- 2024-03-31: Operating Lease, Liability, Current $30.00K.
- 2023-12-31: Operating Lease, Liability, Current $58.00K.
- 2023-09-30: Operating Lease, Liability, Current $92.00K.
- 2023-06-30: Operating Lease, Liability, Current $120.00K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2024-03-31 | $30.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $58.00K 10-K · filed 2025-02-21 |
| 2023-09-30 | $92.00K 10-Q · filed 2023-11-01 |
| 2023-06-30 | $120.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $116.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $110.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $106.00K 10-Q · filed 2022-10-31 |
| 2022-06-30 | $103.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-16 |
| 2020-12-31 | $0.00 10-K · filed 2021-04-16 |
| 2020-09-30 | $82.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $90.00K 10-Q/A · filed 2020-08-18 |
| 2020-03-31 | $105.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $120.00K 10-K · filed 2021-04-16 |
| 2019-09-30 | $134.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $147.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $161.00K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |